康龙化成(03759)预期2025年经调整归母净利同比增长10%-15%
智通财经网·2026-01-13 12:45

Core Viewpoint - The company expects to achieve revenue of approximately 13.872 billion to 14.24 billion yuan in 2025, representing a year-on-year growth of 13% to 16% [1] Financial Performance Summary - The net profit attributable to shareholders is projected to be around 1.614 billion to 1.686 billion yuan, reflecting a year-on-year decline of 6% to 10% [1] - The non-GAAP net profit is estimated to be approximately 1.507 billion to 1.562 billion yuan, indicating a year-on-year increase of 36% to 41% [1] - The adjusted net profit under non-IFRS standards is expected to be about 1.7675 billion to 1.848 billion yuan, showing a year-on-year growth of 10% to 15% [1] Quarterly Performance Expectations - For the fourth quarter of 2025, the company anticipates a year-on-year revenue growth of 14.79% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to increase by 54.09% year-on-year [1] - The adjusted net profit under non-IFRS standards is projected to grow by 16.36% year-on-year [1]

PHARMARON-康龙化成(03759)预期2025年经调整归母净利同比增长10%-15% - Reportify